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Introduction  
Today’s world is one of constant monitoring and tracking – sometimes 
driven by us, sometimes driven by others. Developments in the field of 
health and identity are no exception. New technologies such as wearable 
devices and other technologies in consumer centred healthcare allow us to 
track our fitness and health data, and connect us with others.  
 
Similarly, the rise in direct-to-consumer genetic testing services (“DTC”, 
sometimes known as personal genomics or commercial genomics), can be 
viewed both as an example of emerging technology and also as disruptive 
innovation. These services have created a commercial market for genetic 
tests, allowing people to buy their own DNA tests online without a medical 
intermediary.  
 
However, as with wearable health devices, DTC potentially affords 
opportunities for other entities to access and compile that data and subject 
us to profiling. Consumers therefore need to understand what’s involved 
when we buy our ‘genetic self’ online.  
 
This article provides a brief introduction to the world of DTC and its potential 
traps for the unwary. It discusses some short and longer term regulatory 
measures that may help to iron out the most serious risks to consumer 
privacy. In particular, it concludes that the industry needs more oversight 
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and consumers need more control of their genetic data and personal data 




The growth of ‘direct to consumer’ genetic testing 
The market for DTC has been experiencing significant growth in the last 
couple of years with some prominent DTC companies having databases with 
several million consumers’ samples.  
 
Ancestry testing is particularly popular, but the industry varies widely with 
a broad spectrum of services available. The best known ancestry and health 
tests are provided by prominent companies, such as 23andMe, 
AncestryDNA, Orig3n, MyHeritage, and Family Tree DNA. However, there 
are also companies offering lesser known tests that are often more dubious, 
including assessing child talent; peace of mind paternity; and infidelity 
(often dubbed surreptitious testing). Several of these tests raise privacy 
and ethical concerns.  
 
The proliferation and variety of services on offer are increasingly attracting 
attention from researchers. My own research (due to be published as a 
book later in 2019) included a review of the online contracts of 71 DTC 
companies providing tests for health purposes. It found that a number of 
terms commonly included in these contracts are problematic from a 
consumer protection standpoint. Some companies, such as Soccer 
Genomics, have also resulted in concern from research scientists, with 
Stephen Montgomery at Stanford University launching a parody ‘Yes or No 
Genomics’ website in response. Another parody website, DNA Friend, is a 
useful resource to highlight the sensitive nature of these services. However, 
these parodies do to some extent assume a level of knowledge about 
genetics and we really need more efforts to assist the public in 
understanding the risks here. 
 
While there is increasing public awareness of ancestry and health tests, 
what is less well understood is that these tests are generally not 
standardised and that any entity collecting genetic data could potentially 
use that data for secondary research or share it with third parties, such as 
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law enforcement. This article explores the problems that can arise as a 
result. It also discusses the existing and potential mechanisms that might 
help to resolve those problems.     
A lack of standardisation  
In relation to DTC tests for health purposes, many tests for common 
complex diseases are not harmonised and the validity of their findings is 
open to dispute.  
 
In particular, DTC companies often do not provide whole genome scans and 
instead focus on portions of an individual’s genome. Also, they can focus 
on different genetic variants and also frame their populations differently. 
As a result, it is possible to get contradictory disease risk estimates from 
different companies.  
 
The more common ancestry tests have also not been standardised, and it 
is similarly possible to obtain contradictory ethnicity estimates from 
different companies. There have even been instances of DTC companies 
providing DNA test reports on canine samples without distinguishing them 
from human samples. For example, in their article “Heredity or hoax?” on 
the CBC News website (13 June 2018), Jorge Barrera and Tiffany Fox 
discussed an example where a man had sent a dog DNA sample to a 
company (under a human name) and received an estimate of 20% First 
Nations ancestry.   
 
This means that consumers need be cautious about these services. At the 
very least, the public needs to be provided with more information about the 
limitations of testing. The utility of the service being sold may be limited. 
 
Secondary use of genetic data 
The potential for genetic data to be used in ongoing research is high. A 
number of the most prominent DTC companies have begun to partner with 
the pharmaceutical industry and we have also begun to see investment by 
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the insurance industry in DTC. One challenge here is that it is not possible 
to truly anonymise genetic data. (See for example the work of Yaniv Erlich, 
Science 339, 321–324 (2013)). If something goes wrong, we cannot 
change our stored genetic data in the same way we could change our bank 
password. So it is particularly important that where DTC companies engage 




It is important for consumers to understand the potential for secondary use 
here. The source of profit for DTC companies will often be partnerships and 
mergers with other entities and there is a significant level of uncertainty 
here in relation to the variety of ways in which genetic data could be used 
in the future.   
 
Use for law enforcement is also attracting increasing attention. In the last 
year, there was much media coverage of the genetic genealogy database 
GEDmatch’s involvement in the investigation of the Golden State Killer 
case, where law enforcement accessed its database in order to find a 
potential suspect, through the process of familial DNA matching.  Since this 
revelation, it has emerged that more than 100 other DNA profiles from cold 
cases have been uploaded to GEDmatch. In early 2019 it also emerged that 
the DTC company Family Tree DNA has been working with the FBI to 
investigate violent crime (see for instance Matthew Haag’s article in the 
New York Times on 4 February 2019). 
 
Genetic data is sensitive in nature 
Genetic data is generally viewed as sensitive. It can do real harm in the 
wrong hands. It is also much more than a method of identification in 
criminal proceedings. Genetic data has certain characteristics, which mean 
that it can pose long term privacy risks for individuals and their relatives.  
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Once you have a genetic test, your genetic code is digitised and that digital 
data can be stored potentially indefinitely and used for purposes beyond 
the primary purpose for which you gave it. It can also serve as a unique 
identifier for both you and your genetic relatives (who may be different 
from your family). The impact of a data leak may be substantial, and it 
does not decrease over time.   
 
The industry also operates internationally. Typically, a consumer can 
purchase a test through a website and then they will receive a sample 
collection kit in the mail. This is normally used for the collection of a saliva 
sample or a cheek swab, which the individual then sends back to the 
company for processing. Although services vary, companies will generally 
provide results through a web interface.  
 
From a regulatory perspective, the international nature of the industry 
creates complexity. The physical sample may be sent overseas and 
processed and stored by a company in a different country from where the 
consumer resides. The sequenced genetic data generated from this physical 
sample may or may not be stored in that same country. Also, DTC 
companies may collect other forms of personal data from their consumers 
through surveys and other research activities. Where this is stored may 
also vary, and again may be different from where the consumer resides.  
 
These features, among others, affect how we need to think about regulation 
of businesses that handle genetic data.  
 
The impact of the General Data Protection Regulation on DTC 
Europe’s data protection law, the General Data Protection Regulation 
(“GDPR”) is supposed to put users back in control of their data. It has direct 
relevance to the DTC industry: any company that sells or provides services 
directly to consumers based in the EU needs to ensure that it complies with 
the GDPR.  
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Genetic data is included in the prohibition on processing of special 
categories of data in article 9 of the GDPR. Consequently, in order to comply 
with the GDPR, companies should be obtaining explicit and informed 
consent from their consumers for a DNA test. A more traditional “notice 
and choice” model is insufficient. In my research to date on regulation of 
DTC it seems likely that many businesses will need to alter their consent 
mechanisms in order to meet this higher standard.  
 
Part of the problem is that e-commerce based services have relied on their 
online information (including contracts and privacy policies) to govern 
relationships with consumers. However, providing clear online information 
about complex subjects can be a challenge. Also, we have all grown 
accustomed to ignoring terms and conditions and privacy policies on 
websites. This is due to a number of factors, but one of the most significant 
problems is that people often lack the time to read these documents and 
even where they do take the time, they may struggle to understand their 
contents. Many businesses have created longer contracts and privacy 
policies or terms of service documents which are heavily skewed in favour 
of their interests, rather than those of their consumers. There has also been 
a lack of oversight of these documents. Consumers are deterred from 
reading them and may believe that they are not capable of challenging or 
changing the use of their information in any case.  
 
However, under the GDPR, a high standard of consent is required for data 
processing and it is not going to be acceptable to bury consent in a lengthy 
contract or to only make company policies accessible after a consumer has 
registered for a service. Both under the GDPR and under EU consumer 
protection legislation there are also requirements for these documents to 
be in plain and intelligible language. As contracts and privacy policies are 
often linked together, problematic terms in contracts, which could be 
challenged on consumer protection grounds may also be found to be 
 8 
problematic from a data protection perspective as well. EU consumer 
protection legislation also restricts the inclusion of terms that may be 
deemed to be unfair and limits their enforceability.  
 
As the GDPR beds in, consumers are also starting to realise that they have 
genuine mechanisms to challenge what companies are doing with their 
data. The recurring and self-serving rhetoric expressed by some key 
players in Big Tech that ‘privacy is dead’ is changing. We are starting to 
see a shift with wide-reaching laws such as the GDPR, together with growth 
in mega data breaches, and calls for further regulation. Privacy is not only 
still alive – it is kicking. For example, the most recent Annual Report 
released by the Irish Data Protection Commissioner (which is the first line 
of regulation for many tech companies in Europe) demonstrates that people 
do care about their privacy and that complaints lodged under the GDPR are 
likely to increase.  
 
Many countries outside the EU are also reforming their privacy and data 
protection laws to cater for new developments. Simply stopping marketing 
DTC services to EU consumers, to avoid coverage by the GDPR, is therefore 
unlikely to be a viable solution. DTC companies will increasingly need to 
meet similar legal requirements for consumers based outside the EU.  
 
Suggestions for reform 
 
The DTC industry has grown in the last two decades with relatively little 
oversight, during which time the potential of the technology has grown 
immensely. A number of policy documents have been released by diverse 
bodies, which could be drawn upon in improving industry governance. For 
example, the UK’s Science and Technology Committee has recently begun 
an inquiry into Commercial Genomics and is seeking public submissions. It 
is hoped that this inquiry will lead to improved oversight of the DTC industry 
in the UK and may provide useful guidance for other countries considering 
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how to regulate the industry. The UK’s disbanded Human Genetics 
Commission also previously developed a Common Framework of Principles, 
which could be drawn upon in developing new legislation or industry codes 
of conduct.  
 
Below are some further suggestions for both short term and long term 
strategies. There is no perfect solution, but a number of steps could lead 
to significant improvements for consumers and for improving standards 
across the industry. 
 
In the short term: 
• The public needs more independent informational resources to assist 
them in making informed decisions about whether or not to utilise 
DTC services. Data protection authorities and privacy regulators as 
well as consumer regulators could release statements in relation to 
the industry. The Office of the Canadian Privacy Commissioner has 
already begun to take steps in this direction. It has released a number 
of documents in relation to DTC, including recommendations for 
questions that consumers could ask DTC companies, and questions 
that they should ask themselves when considering purchasing a test.  
This example could provide a useful model for other regulators 
exploring these issues. 
• Existing regulators should also consider developing industry codes of 
conduct and model privacy policies and consumer contracts. One 
potential foundation for such a code is the Future of Privacy Forum’s 
paper “Privacy Best Practices for Consumer Genetic Testing Services” 
(June 2018), which was developed in collaboration with some 
prominent DTC companies. This document makes a number of 
positive commitments in relation to privacy, but it is voluntary and it 
remains to be seen how businesses will adhere to this. Unlike the 
Future of Privacy Forum paper, though, any code should make it clear 
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that American companies selling genetic tests to consumers based in 
the EU should still be complying with the GDPR.  
• Another model is to make codes of conduct mandatory for the 
industry to follow. There may be reasonable support for such a move: 
DTC companies that wish to engage in health research and maintain 
consumer trust have an interest in showing that they comply with the 
law and support improvement of industry standards. They will wish 
to distance themselves from more dubious types of tests. 
• Businesses should rethink their drafting of contracts and privacy 
policies. In relation to contracts, clauses that significantly limit 
consumers’ rights should be avoided. For example, if businesses wish 
to be compliant with the GDPR and applicable consumer protection 
legislation then they should not include clauses that allow them to 
change their terms at any time without notice to the consumer.  
• Businesses should also think about their interface design. Given the 
sensitive nature of genetic data and the complex nature of some 
health test results, consumers should not be rushed into making a 
purchase. Putting speed bumps into the process, which encourage 
reflection and allow consumers to change their minds could help to 
achieve compliance with the GDPR. It would be beneficial for 
businesses to allow for a cooling off period as well in between 
purchase and processing of the sample.  
• Businesses should also improve their practices in relation to deletion 
and destruction of physical samples and data. It should be possible 
for any company performing a genetic test to provide their consumers 
with the option of deleting the data and destroying the sample after 
sending the consumer their test results. Guardiome is an interesting 
example here, as they offer consumers their whole genome sequence 
on a device and their approach seems to be more privacy centric.  
• Businesses should also keep in mind the GDPR’s principles in relation 
to data processing. In the context of DTC, adhering to the data 
minimisation principle could be particularly beneficial.  
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• At the national level, privacy and data protection regulators as well 
as consumer protection regulators should play a role in improving 
industry governance. Compliance reviews of privacy policies, 
contracts, and personal data practices, particularly in relation to 
security practice would all be beneficial for improving industry 
governance.   
 
In the longer term: 
• We need more specific oversight of the industry in order to improve 
standards and ensure the protection of privacy and consumer rights 
more generally. One possibility is the creation of new regulatory 
bodies with a mandate to regulate all businesses that handle genetic 
data. This could draw upon existing models of data protection 
authorities and financial services regulators and in some countries, 
this could be a new body that was under the oversight of the data 
protection authority. 
• Tests of more dubious validity, such as surreptitious tests and child 
talent should be banned and regulators should help to alert the public 
about the most problematic services. In the UK, the Human Tissue 
Act makes it an offence to analyse DNA without appropriate consent 
and it is likely that any company offering surreptitious tests to UK 
consumers is likely to be in breach of this. 
• New legislation dealing more specifically with individual’s rights in 
genetic data is needed. The recent Canadian Genetic Non-
Discrimination Act could provide a useful model for other countries 
considering how to strengthen the rights of citizens in their genetic 
data. 
• New industry specific legislation should also be introduced at a nation 
level and international collaboration to develop more universal 
standards that could be followed globally could also help consumers 
given the international nature of these services. 
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This article has provided an introduction to the world of DTC and the 
challenges the industry poses for privacy. It is vital to understand that there 
is also a lot of uncertain risk in this context. We do not know all the ways 
that our genetic data could be used in the future, but given that we cannot 
change our genetic data and that it can always potentially be linked back 
to us, can be used for many different purposes, and can also be used to 
trace our family members, reform is needed. People do need protection of 
their rights in this space and businesses should also view this as an 
opportunity to do things differently.  
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